Marksans Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

The quarterly results for Marksans Pharma Limited (NSE:MARKSANS) were released last week, making it a good time to revisit its performance. It was not a great result overall. Although revenues beat expectations, hitting ₹9.4b, statutory earnings missed analyst forecasts by 11%, coming in at just ₹3.11 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the consensus forecast from Marksans Pharma's three analysts is for revenues of ₹35.7b in 2027. This reflects a credible 5.2% improvement in revenue compared to the last 12 months. Statutory per share are forecast to be ₹12.55, approximately in line with the last 12 months. Before this earnings report, the analysts had been forecasting revenues of ₹35.7b and earnings per share (EPS) of ₹11.85 in 2027. So the consensus seems to have become somewhat more optimistic on Marksans Pharma's earnings potential following these results.

See our latest analysis for Marksans Pharma

The consensus price target was unchanged at ₹324, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Marksans Pharma, with the most bullish analyst valuing it at ₹385 and the most bearish at ₹210 per share. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's pretty clear that there is an expectation that Marksans Pharma's revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 11% growth on an annualised basis. This is compared to a historical growth rate of 17% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 12% annually. Factoring in the forecast slowdown in growth, it looks like Marksans Pharma is forecast to grow at about the same rate as the wider industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Marksans Pharma's earnings potential next year. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target held steady at ₹324, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Marksans Pharma going out to 2029, and you can see them free on our platform here..

We also provide an overview of the Marksans Pharma Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.